Reset filters
30 November 2023

In this Community Call, we discussed:

  • Altered Smooth Muscle Cell Histone Acetylome by the SPHK2/S1P Axis Promotes Pulmonary Hypertension
  • Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial
  • Impact on Pulmonary Hypertension Hemodynamic Classification Based on the Methodology Used to Measure Pulmonary Artery Wedge Pressure and Cardiac Output
PVRI Community Calls
14 November 2023

Webinar presentations: Improving accuracy in prognosis in PAH Prognostic Scoring Systems – REVEAL 2.0 onwards, Raymond Benza; Integration of mutational profile into PAH Risk Calculators for better assessment of prognosis, Eric Austin; Integration of biomarkers into PAH Risk Calculators for better assessment of prognosis, Anna Hemnes

Members Only
27 October 2023

In this Community Call, we discussed: 

  • Targeting Wnt-ß-Catenin-FOSL Signaling Ameliorates Right Ventricular Remodeling
  • Win Statistics in PAH Clinical Trials
  • Evaluation of a digital health system (PAHcare™) for routine care of patients with pulmonary arterial hypertension: The CBS-PAH study protocol
PVRI Community Calls
5 September 2023

In this Community Call, we discussed: 

  • Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension
  • Elastin stabilization prevents impaired biomechanics in human pulmonary arteries and pulmonary hypertension in rats with left heart disease
PVRI Community Calls
11 July 2023

Presented at PVRI 2023 Drug Development and Discovery Symposium (DDDS) by Alex Dusek, Polarean Imaging, & Benjamin Lavon, Fluidda

Members Only